Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Adizem-XL
- Development stage
- Unknown
- Lead developer
- Napp Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Adizem-XL is an extended-release formulation of diltiazem hydrochloride, a benzothiazepine calcium channel blocker developed and marketed by Napp Pharmaceuticals. It is primarily indicated for the management of angina pectoris and the treatment of mild to moderate hypertension. The drug works by inhibiting L-type (voltage-gated) calcium channels in cardiac and vascular smooth muscle, which leads to peripheral and coronary vasodilation, a reduction in heart rate, and decreased myocardial contractility. This once-daily oral capsule formulation is designed to provide a sustained therapeutic effect over a 24-hour period, eliminating high peak plasma concentrations and improving patient compliance compared to immediate-release alternatives.
- Brand names
- Adizem-XL
- Other names
- Diltiazem hydrochloride
02
Targets
CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)LTCC (Voltage-gated calcium channel (L-type))
Beyond the preview
Go deeper on Adizem-XL.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Adizem-XL.